JP2022527482A5 - - Google Patents

Info

Publication number
JP2022527482A5
JP2022527482A5 JP2021557790A JP2021557790A JP2022527482A5 JP 2022527482 A5 JP2022527482 A5 JP 2022527482A5 JP 2021557790 A JP2021557790 A JP 2021557790A JP 2021557790 A JP2021557790 A JP 2021557790A JP 2022527482 A5 JP2022527482 A5 JP 2022527482A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
erdafitinib
dose
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/058814 external-priority patent/WO2020201138A1/en
Publication of JP2022527482A publication Critical patent/JP2022527482A/ja
Publication of JP2022527482A5 publication Critical patent/JP2022527482A5/ja
Priority to JP2025230741A priority Critical patent/JP2026048748A/ja
Pending legal-status Critical Current

Links

JP2021557790A 2019-03-29 2020-03-27 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 Pending JP2022527482A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025230741A JP2026048748A (ja) 2019-03-29 2025-12-04 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
EP19166429.1 2019-03-29
US201962833395P 2019-04-12 2019-04-12
US62/833,395 2019-04-12
PCT/EP2020/058814 WO2020201138A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025230741A Division JP2026048748A (ja) 2019-03-29 2025-12-04 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2022527482A JP2022527482A (ja) 2022-06-02
JP2022527482A5 true JP2022527482A5 (cg-RX-API-DMAC7.html) 2024-07-24

Family

ID=69954076

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557790A Pending JP2022527482A (ja) 2019-03-29 2020-03-27 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤
JP2025230741A Pending JP2026048748A (ja) 2019-03-29 2025-12-04 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025230741A Pending JP2026048748A (ja) 2019-03-29 2025-12-04 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤

Country Status (15)

Country Link
US (1) US20220175768A1 (cg-RX-API-DMAC7.html)
EP (2) EP3946340A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022527482A (cg-RX-API-DMAC7.html)
KR (1) KR20210143878A (cg-RX-API-DMAC7.html)
CN (1) CN113645975A (cg-RX-API-DMAC7.html)
AU (1) AU2020253054B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019203A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130773A1 (cg-RX-API-DMAC7.html)
IL (1) IL286727A (cg-RX-API-DMAC7.html)
JO (1) JOP20210260A1 (cg-RX-API-DMAC7.html)
MA (1) MA55486A (cg-RX-API-DMAC7.html)
MX (1) MX2021011943A (cg-RX-API-DMAC7.html)
PH (1) PH12021552352A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109854RA (cg-RX-API-DMAC7.html)
WO (1) WO2020201138A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011926A (es) 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
US20230321087A1 (en) * 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
WO2022243467A1 (en) * 2021-05-19 2022-11-24 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
AU2022289906A1 (en) * 2021-06-07 2023-11-09 R.P. Scherer Technologies, Llc Protective coating for moisture sensitive pharmaceutical compositions
IL312063A (en) 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
WO2023159216A1 (en) 2022-02-18 2023-08-24 Taris Biomedical Llc Erdafitinib formulations and osmotic systems for intravesical administration
CN116106240B (zh) * 2022-12-26 2025-11-07 华中农业大学 一种尿液酪氨酸检测体系、检测方法及检测试剂盒
IL322667A (en) 2023-02-13 2025-10-01 Taris Biomedical Llc Ardepitinib for intravesical administration for use in the treatment of bladder cancer
CN120731077A (zh) 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Similar Documents

Publication Publication Date Title
EP4337191B1 (en) Egfr inhibitor for the treatment of head and neck cancer
Takahashi et al. High-dose intravenous vitamin C improves quality of life in cancer patients
Sanchez-Lopez et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling
CN109310754A (zh) 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
RU2012153963A (ru) Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами
Kanda et al. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy
JP2025038167A (ja) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
Adhikaree et al. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy
JP2023513298A5 (cg-RX-API-DMAC7.html)
Alexandraki et al. Medical therapy for craniopharyngiomas
Nelson et al. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer
JP2022527189A5 (cg-RX-API-DMAC7.html)
Shihab et al. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study
JP2025509278A (ja) 小細胞肺癌を治療する方法
Fujimoto et al. Successful treatment with ramucirumab plus erlotinib following osimertinib-induced interstitial lung disease
TW202237100A (zh) 使用包含gdc-9545及gdc-0077之組合療法治療乳癌
US20220348662A1 (en) Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
Calvo et al. Management of mTOR inhibitors oral mucositis: current state of knowledge
Hashmi et al. The effects of voriconazole on metabolism of all-trans retinoic acid in the treatment of acute promyelocytic leukemia: a case report
KR20230132496A (ko) 고정 용량의 타미바로텐을 사용하는 치료 용법
de Bono et al. Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)
KR102895850B1 (ko) Isa-2011b와 엘로티닙을 포함하는 암 예방 또는 치료를 위한 병용 투여용 약학적 조성물
Chiba et al. Deterioration of glycemic control contributes to the prevalence of proteinuria among bevacizumab-treated cancer patients with type 2 diabetes mellitus
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers